ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Net Income
Bottom-line profit after all expenses, interest, and taxes.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$9.55M, compared with -$6.03M a year earlier. Trailing-twelve-month net income was -$29.07M.
Context
- Net income amounted to 69.1% of revenue in FY2025, up 8.8 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$32.99M (-29.2%) for the fiscal year ending Dec 2026, a step up from the -35.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.55M-22.7% QoQ
- Last fiscal yearDec 2025
- -$25.54M-35.0% YoY
- LTMMar 2026
- -$29.07M-39.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -58.5% | -52.2% | +6.3 pp |
| 1 year | -35.0% | -29.2% | +5.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (25.54M) USD
- Year-over-year change
- -35.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.54M) | -35.0% |
| FY2024 | 2024-12-31 | (18.91M) | +14.4% |
| FY2023 | 2023-12-31 | (22.09M) | -34.4% |
| FY2022 | 2022-12-31 | (16.44M) | -14.1% |
| FY2021 | 2021-12-31 | (14.41M) | — |
Net Income vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.8% is the 8th highest of 10, against a peer median of +37.1%.
- Net income amounts to 71.6% of revenue for CLPT, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -CA$10.98M CAD | +89.7% | — | 1.2% | |
| LTM Mar 2026 | -$16.7M USD | +37.1% | — | 8.1% | |
| LTM Mar 2026 | -$20.51M USD | +54.7% | — | 8.8% | |
| LTM Mar 2026 | -$29.07M USD | -39.8% | — | 71.6% | |
| LTM Mar 2026 | -$60.01M USD | +58.1% | — | 7.3% | |
| LTM Mar 2026 | -$69.4M USD | +82.0% | — | 9.7% | |
| LTM Mar 2026 | -$74M USD | -557.7% | — | 36.2% | |
| LTM Apr 2026 | -$82.7M USD | -96.9% | — | 9.6% | |
| LTM Mar 2026 | -$94.08M USD | +29.1% | — | 109.1% | |
| LTM Mar 2026 | -$178.95M USD | -29.9% | — | — | |
| Peer median (excluding CLPT) | — | +37.1% | — | 9.2% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.